Vericel Reports First-Quarter 2016 Financial Results
May 10, 2016 07:30 ET
|
Vericel Corporation
Total Revenues of $14.1 Million Reported for the Quarter Carticel and Epicel Revenues Increase 31% versus First Quarter 2015 Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., May ...
Vericel to Host First-Quarter 2016 Earnings Webcast and Conference Call on May 10, 2016
April 27, 2016 16:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., April 27, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases...
Vericel to Present at 15th Annual Needham Healthcare Conference
April 08, 2016 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., April 08, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases...
Results from Vericel’s Positive Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T Presented Today at ACC and Published in The Lancet
April 04, 2016 11:45 ET
|
Vericel Corporation
CAMBRIDGE, Mass., April 04, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and...
Vericel to Host Review of Positive Phase 2b ixCELL-DCM Trial Results Following American College of Cardiology 65th Annual Scientific Sessions
March 29, 2016 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., March 29, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and...
Vericel Announces Publication of Clinical Trial Rationale and Study Design for the Phase 2b ixCELL-DCM Trial of Ixmyelocel-T in Patients with Heart Failure Due to Ischemic Dilated Cardiomyopathy
March 28, 2016 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., March 28, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and...
Vericel Reports Fourth-Quarter and Year-End 2015 Financial Results
March 14, 2016 07:45 ET
|
Vericel Corporation
Total Revenues of $15.4 Million Reported for the Fourth Quarter Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation...
Vericel Announces Positive Top-Line Results From Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T in Patients With Heart Failure Due to Ischemic Dilated Cardiomyopathy
March 10, 2016 08:00 ET
|
Vericel Corporation
CAMBRIDGE, Mass., March 10, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and...
Vericel Enters Into $10 Million Credit Facility and $5 Million Term Loan Agreement With Silicon Valley Bank
March 09, 2016 08:00 ET
|
Vericel Corporation
CAMBRIDGE, Mass., March 09, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and...
Vericel to Present at 28th Annual ROTH Conference
March 08, 2016 16:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., March 08, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and...